Halberd Corp (HALB)

[docsetc]

They are constantly in initial test-mode and their antibody research and related patents are so far behind Gilead, ENZC, and Merck, that they won't be catching up for a profitable market release.

These guys are studying an interesting alternative, but their methods will be antiquated and considered last resort with all of the successes of others in this same monoclonal antibody arena, who are far, far more ahead of them with proven clinical trials already.

Merck, Gilead, and ENZC all have tested results quantum leaps ahead of the Halberd operation. Best market trackers say Giliad may be in talks already to license the ENZC properties and patented treatments. Final Stage IV/EMA approvals for ENZC begin this August, Merck is suppose to begin their final trials in December, and Gilead may just convert over to using ENZC's stuff in a licensing agreement.

Halberd does not even have real results yet in a test scenario, just design dreams. The others have treatments that will never require the process to be done outside the body, in fact, that is a reversal of the best use of monoclonal antibodies.

HALB has been caught in so many cases of fraud in the past, and their CEO is a doofus. I would not be surprised to see this one burn up in smoke Oscar. Anyone can patent a useless product design.